恒瑞医药(600276.SH)子公司SHR-2906注射液获批临床试验

Core Viewpoint - Heng Rui Medicine (600276.SH) has received approval from the National Medical Products Administration for clinical trials of SHR-2906 injection, a self-developed therapeutic biological product aimed at weight control and metabolic regulation [1] Group 1: Product Development - SHR-2906 injection is designed to reduce energy intake and promote energy expenditure, potentially improving metabolic conditions and offering clinical efficacy in treating overweight and obesity [1] - Currently, there are no similar drugs approved for market release domestically or internationally [1] Group 2: Financial Investment - The total research and development investment for the SHR-2906 injection project has reached approximately 17.06 million yuan [1]